PatientsVisitorsLocations & ServicesAbout the RegionJoin Our TeamPhysicians
Find:  Locations | Services
Pathology and Laboratory Medicine HomeTest and Services CatalogueTransfusion Medicine Product CataloguePolicy and ProcedureJob AidsSpecimen Collection and TransportRequisitionsAntibiogramsGenetic Testing and Molecular GeneticsMicrobiology EssentialsTransfusion EssentialsReference RangesLaboratory SuppliesAcute Care SCM GuidelinesContact InformationPhysician Access to Patient ResultsOpening A New Clinic
Pathology and Laboratory Medicine
Test Catalogue

​bcr-abl t(9;22) p210 fusion RT-PCR (bcr-abl)

Human Molecular Genetics


​Ordering Recommendation

  • ​ ​Due to the instability of RNA transcripts, specimens are recommended to be collected Mon-Thurs
  • This is an RNA based test and can be repeated for patient management
  • If JAK-2 and bcr-abl are both requested, two tubes of peripheral blood are sufficient for both tests
  • The bcr-abl rearrangement may be detected by RT-PCR, even when no Philadelphia chromosome is observed by cytogenetic analysis

​ ​Specimen Requirements

Type​
  • ​Bone marrow aspirate
  • Whole blood
​Container
​Collection Procedure
  • ​Invert several times to mix
  • Specimens should be transported to Royal University Hospital, Human Molecular Genetics without unnecessary delay
​Required Volume

Peripheral Blood

  • Optimal Volume: 8 ml  (2x Lavender tubes)
  • Minimum Volume: 4 ml

Bone Marrow Aspirate

  • Optimal Volume: 3 ml
  • Minimum Volume: 1 ml
​Stability/Storage
  • ​RNA molecules are not stable and degrade over time. Timely transport is important
  • Ship specimens at ambient temperature
  • Specimens may be stored at 2 - 8°C before being immediately processed
Grounds for Rejection​

Testing Information​ ​

Availability​
  • ​Recommended collection Monday -Thursday
  • STAT testing can be requested, but testing only available Monday to Friday
Testing Site​Royal University Hospital, Human Molecular Genetics Laboratory
Results Reporting​
  • ​Results are generally available within 7 working days
  • STAT results are available within 3 working days
​Methodology
  • ​RNA is reverse-transcribed into cDNA and subjected to PCR amplification
  • This analysis provides qualitative information only
​Clinical Interpretation
  • ​Presence or absence of the bcr-abl t(9;22) p210 fusion transcript
​Specimen Retention
  • ​Frozen cell pellet (if sufficient sample) retained for 2 years
  • Unprocessed samples can not be retained for future testing
Alternate Test Names​
  • Chromosomes 9 and 22 translocation fusion product
  • t(9;22)
  • CML (Chronic Myelogenous Leukemia)
  • Philadelphia chromosome transcript
​Additional Comments
  • ​This test does not detect the alternate t(9;22) p190 fusion transcript occurring from a break in the minor breakpoint cluster region
  • This test is not suitable for Minimal Residual Disease testing
​SHR LIS Test Code
  • ​Order as MISTC (For Laboratory Use Only)



​If you choose to print this information, it is valid only on date of print.

Laboratory Controlled Document LSM-334 v3

Last Modified: Monday, September 9, 2019 |
Questions or feedback about this page?